Sona Nanotech (CSE:SONA, OTCQB:SNANF) advances nanotechnology medicine through its proprietary gold nanorods that promise to change the face of cancer therapy. Sona Nanotech’s platform technology leverages uniquely biocompatible gold nanorods (GNRs). Biocompatibility is key to the application of nanotechnology in medicine.

For the past several years, Sona has been working hard to develop and operationalize its biocompatible nanoparticle technology for use in targeted cancer therapy. The company is also developing a targeted cancer therapy, leveraging its proprietary Targeted Hyperthermia Therapy (THT) to directly treat cancer cells.

Sona’s GNRs are rod-shaped nanoparticles made of gold and measuring from 10 to 100 nanometers in length. Produced by chemical synthesis, they directly address many of the current limitations of medical nanoparticle technologies. In addition to making them well-suited for cancer treatment, this also unlocks their potential for use in in-vivo medical applications.

Company Highlights

Canadian nanotechnology company, Sona Nanotech has developed an incredibly promising new technology that leverages uniquely biocompatible gold nanorods.The company also plays a key role in the advancement of photothermal medical therapies, particularly enabled by the company’s acquisition of Siva Therapeutics.This acquisition has allowed Sona to advance the development of Targeted Hypothermia Therapy, addressing many of the risks with current cancer treatments — particularly the damage they can cause to other tissues.THT has already proven effective in reducing tumors in small animal studies. Sona’s initial target for the technology will be colorectal cancer.Rapid diagnostic tests represent the company’s other strategic area of focus, including bovine tuberculosis detection and concussion screening.Future applications for Sona’s technology could include:Targeted drug deliveryPhotothermal cosmetic therapyCell imagingAdditional proprietary testing solutions supported by third-party test development services.The company’s leadership and board of directors comprise experienced professionals from across the healthcare and biotechnology sectors.Sona has a clear roadmap to commercialization of its treatment methodology, starting with a near-term catalyst in large animal studies before moving to a human pilot. It also expects a De Novo pathway for medical devices.

This Sona Nanotech is part of a paid investor education campaign.*

Click here to connect with Sona Nanotech (CSE:SONA) to receive an Investor Presentation